NewAmsterdam Pharma
Developing transformative, clinically validated oral therapies for patients with metabolic diseases.
Market cap
$2.1b
Enterprise value
$1.3b
Share price
$18.11 NAMS
Company register number
05266586
loading funding rounds…
Forbion Capital Partners(exited)
Morningside(exited)
Ascendant BioCapital(exited)
EQT Life Sciences(exited)
BioGeneration Ventures(exited)
JVC Investment Partners(exited)
Frazier Healthcare Partners(exited)
RA Capital Management(exited)
GMT Capital(exited)
Medicxi(exited)
Panacea Venture(exited)
Bain Capital Life Sciences(exited)
Population Health Partners(exited)
Frazier Life Sciences(exited)
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (87 %) | 223 % | (58 %) | (20 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (7 %) | (1218 %) | (350 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (80 %) | (1256 %) | (530 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 85 % | 1131 % | 332 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.